The heterogeneity of the ALL subtypes makes a general therapeutic strategy that directly targets the important inhibitory phosphatase SHIP1 difficult, since SHIP1 is differently expressed in the various subgroups of ALL. This evidence concerns the gene INPP5D and acute lymphoblastic leukemia.